DOI: https://dx.doi.org/10.18565/pharmateca.2022.7.71-77
Поддубная И.В., Огнерубов Н.А., Антипова Т.С.
1) Российская медицинская академия непрерывного профессионального образования, Москва, Россия; 2) Тамбовский государственный университет им. Г.Р. Державина, Тамбов, Россия; 3) ООО Центр ядерной медицины «Центр ПЭТ Технолоджи», Тамбов, Россия
1. Jamieson B.D., Douek D.C., Killian S., et al. Generation of functional thymocytes in the human adult. Immunity. 1999;10:569–75. Doi: 10.1016/S1074-7613(00)80056-4. 2. Choyke P.L., Zeman R.K., Gootenberg J.E., et al. Thymic atrophy and regrowth in response to chemotherapy. AJR Am J Roentgenol 1987;149:269–72. Doi: 10.2214/ ajr.149.2.269. 3. Sun D.P., Jin H., Ding C.-Y., et al. Thymic hyperplasia after chemotherapy in adults with mature B cell lymphoma and its influence on thymic output and CD4+T cells repopulation. OncoImmunology. 2016;5(5):e1137417. Doi: 10.1080/2162402x.2015.1137417. 4. Cohen M., Hill C.A., Cangir A., Sullivan M.P. Thymic rebound after treatment of childhood tumors. AJR Am J Roentgenol 1980;135:151– 56. Doi: 10.2214/ajr.135.1.151 5. Lin T.L., Shih L.Y., Hung Y.S., Kuo T.T. Thymic hyperplasia following successful chemotherapy for Hodgkin’s lymphoma: report of a case. Chang Gung Med J. 2009;32:98–103. 6. Sun D.P., Wang L., Ding C.Y., et al. Investigating factors associated with thymic regeneration after chemotherapy in patients with lymphoma. Front Immunol. 2016;7:654. Doi: 10.3389/ fimmu.2016.00654. 7. Boehm T., Swann J.B. Thymus involution and regeneration: two sides of the same coin? Nat Rev Immunol. 2013;13(11):831–38. 8. Anchisi S., Abele R., Guetty-Alberto M., Alberto P. Management of an isolated thymic mass after primary therapy for lymphoma. Ann Oncol. 1998;9:95–100. Doi: 10.1023/a:1008220211849. 9. Ferdinand B., Gupta P., Kramer E.L. Spectrum of thymic uptake at 18F-FDG PET. Radiographics. 2004;24:1611–16. 10. Fallanca F., Giovacchini G., Ponzoni M., et al. Cervical thymic hyperplasia after chemotherapy in an adult patient with Hodgkin lymphoma: a potential cause of falsepositivity on 11. Sfikakis P.P., Gourgoulis G.M., Moulopoulos L.A., et al. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur J Clin Invest. 2005;35:380–87. Doi: 10.1111/j.1365-2362.2005.01499.x. 12. Ustaalioglu B.B.O., Seker M., Bilici A., et al. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma. Med Oncol. 2010; 28(1):258–64. Doi: 10.1007/s12032-010-9446-y. 13. Qiu L., Zhao Y., Yang Y., et al. Thymic rebound hyperplasia post-chemotherapy mistaken as disease progression in a patient with lymphoma involving mediastinum: a case report and reflection. BMC Surger. 2021;21(1). Doi: 10.1186/s12893-021-01048-y. 14. Lazaro-Garcia A., Lacalle-Gonzalez C., Santonja C., et al. Post-Chemotherapy Rebound Thymic Hyperplasia Mimicking Relapse in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report. Oncol Res Treat. 2021;44(4):196– 200. Doi: 10.1159/000515055. 15. Brink I., Reinhardt M.J., Hoegerle S., et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med. 2001;42:591–95. 16. Chen C.H., Hsiao C.C., Chen Y.C., et al. Rebound thymic hyperplasia after chemotherapy in children with lymphoma. Pediatr Neonatol. 2017;58(2):151–57. Doi: 10.1016/j. pedneo.2016.02.007. 17. Sehbai A.S., Tallaksen R.J., Bennett J., Abraham J. Thymic Hyperplasia after Adjuvant Chemotherapy in Breast Cancer. J Thorac Imaging. 2006;21(1):43–6. Doi: 10.1097/01. rti.0000185143.17436.f9. 18. Langer C.J., Keller S.M., Erner S.M. Thymic hyperplasia with hemorrhage simulating recurrent Hodgkin disease after chemotherapy-induced complete remission. Review Cancer. 1992;70(8):2082–86. Doi: 10.1002/ 1097-0142(19921015)70:8<2082::aid-cncr2820700812>3.0.co;2-6. 19. Tung-Liang Lin, Lee-Yung Shih, Yu-Shin Hung, Tseng-Tong Kuo. Thymic hyperplasia following successful chemotherapy for Hodgkin’s lymphoma: report of a case. Chang Gung Med J. 2009;32(1):98–103. 20. Son S.K., Park S.S., Kim Y.D., et al. Ectopic thymic hyperplasia in a patient treated for Burkitt lymphoma. J Pediatr Hematol Oncol. 2007;29:506–8. Doi: 10.1097/ MPH.0b013e3180986e2f. 21. Hao-Ran Li, Jian Gao, Chun Jin, Jia-Hao Jiang, Jian-Yong Ding. Comparison between CT and MRI in the Diagnostic Accuracy of Thymic Masses. J Cancer. 2019;10(14):3208–13. Doi: 10.7150/jca.30240. 22. Nakahara T., Fujii H., Ide M., et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol. 2001;74:821–24. Doi: 10.1259/ bjr.74.885.740821. 23. Hasson D., Schiappacasse G. Revisiting a Forgotten Organ: Thymus Evaluation by PET-CT. Julia Alegria2 Claudio Silva Rev. Argent. Radiol. 2020;84:55–60. 24. Liu Y. Characterization of thymic lesions with F-18 FDG PET-CT: an emphasis on epithelial tumors. Nucl Med Commun. 2011;32 (07):554–62. Doi: 10.1097/MNM.0b013e328345b984. 25. Smith C.S., Schoder H., Yeung H.W.D. Thymic Extension in the Superior Mediastinum in Patients with Thymic Hyperplasia: Potential Cause of False-Positive Findings on 18F-FDG PET/CT. Am J Roentgenol. 2007;188(6): 1716–21.
Автор для связи: Николай Алексеевич Огнерубов, д.м.н, к.ю.н, профессор, заслуженный работник высшей школы РФ, заслуженный врач РФ, зав. кафедрой онкологии, Тамбовский государственный университет им. Г.Р. Державина, Тамбов, Россия; ognerubov_n.a@mail.ru ORCID:
Поддубная И.В. (I.V. Poddubnaya), https://orcid.org/0000-0002-0995-1801
Огнерубов Н.А. (N.A. Ognerubov), https://orcid.org/0000-0003-4045-1247